PLD3 and Parkinson disease: Next, by immunohistochemistry using HPA012800, we studied the expression of PLD3 immunoreactivity in the frontal cortex and the hippocampus of 10 AD cases and 13 non-AD cases, composed of four non-neurological cause controls, four amyotrophic lateral sclerosis patients, three Parkinson’s disease patients, and two multiple system atrophy cases (Table 1).